These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 36592248)
41. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. Sandres K; Dubois M; Pasquier C; Payen JL; Alric L; Duffaut M; Vinel JP; Pascal JP; Puel J; Izopet J J Virol; 2000 Jan; 74(2):661-8. PubMed ID: 10623727 [TBL] [Abstract][Full Text] [Related]
42. Genetic diversity and evolution of hepatitis C virus--15 years on. Simmonds P J Gen Virol; 2004 Nov; 85(Pt 11):3173-3188. PubMed ID: 15483230 [TBL] [Abstract][Full Text] [Related]
43. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Fofana I; Fafi-Kremer S; Carolla P; Fauvelle C; Zahid MN; Turek M; Heydmann L; Cury K; Hayer J; Combet C; Cosset FL; Pietschmann T; Hiet MS; Bartenschlager R; Habersetzer F; Doffoël M; Keck ZY; Foung SKH; Zeisel MB; Stoll-Keller F; Baumert TF Gastroenterology; 2012 Jul; 143(1):223-233.e9. PubMed ID: 22503792 [TBL] [Abstract][Full Text] [Related]
44. Innate and adaptive immune responses in HCV infections. Heim MH; Thimme R J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342 [TBL] [Abstract][Full Text] [Related]
45. Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Kang W; Shin EC Yonsei Med J; 2011 Nov; 52(6):871-8. PubMed ID: 22028149 [TBL] [Abstract][Full Text] [Related]
46. [HCV genome variability in acute and chronic viral hepatitis C]. Iushchuk ND; Klimova EA; Znoĭko OO; Gadzhikulieva MM; Il'ina EN; Iashina TL; Malyshev NA; Tsyganova EV Ter Arkh; 2009; 81(4):47-55. PubMed ID: 19514422 [TBL] [Abstract][Full Text] [Related]
47. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Sarrazin C; Zeuzem S Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612 [TBL] [Abstract][Full Text] [Related]
48. RNA-Dependent RNA Polymerase of the Second Human Pegivirus Exhibits a High-Fidelity Feature. Chen S; Wu J; Yang X; Sun Q; Liu S; Rashid F; Dzakah EE; Wang H; Wang J; Gong P; Tang S Microbiol Spectr; 2022 Oct; 10(5):e0272922. PubMed ID: 35980196 [TBL] [Abstract][Full Text] [Related]
49. [Characteristics of the hepatitis C virus and viral predictors of therapeutic response]. Ambrosch A; König W Med Klin (Munich); 1999 Nov; 94(11):626-32. PubMed ID: 10603734 [TBL] [Abstract][Full Text] [Related]
50. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries. Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600 [TBL] [Abstract][Full Text] [Related]
51. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. Cento V; Mirabelli C; Salpini R; Dimonte S; Artese A; Costa G; Mercurio F; Svicher V; Parrotta L; Bertoli A; Ciotti M; Di Paolo D; Sarrecchia C; Andreoni M; Alcaro S; Angelico M; Perno CF; Ceccherini-Silberstein F PLoS One; 2012; 7(7):e39652. PubMed ID: 22792183 [TBL] [Abstract][Full Text] [Related]
53. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients. Sede MM; Laufer NL; Quarleri J Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213 [TBL] [Abstract][Full Text] [Related]
54. Breakthroughs in hepatitis C research: from discovery to cure. Manns MP; Maasoumy B Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):533-550. PubMed ID: 35595834 [TBL] [Abstract][Full Text] [Related]
55. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture. Oraby AK; Gardner CL; Needle RF; Kofahi HM; Everard KR; Taylor NGA; Rutihinda SG; Barry JP; Hirasawa K; Georghiou PE; Russell RS Microbiol Spectr; 2021 Sep; 9(1):e0043921. PubMed ID: 34319169 [TBL] [Abstract][Full Text] [Related]
56. Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy. Anjum S; Afzal MS; Ahmad T; Aslam B; Waheed Y; Shafi T; Qadri I Mol Med Rep; 2013 Aug; 8(2):487-92. PubMed ID: 23799612 [TBL] [Abstract][Full Text] [Related]
57. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967 [TBL] [Abstract][Full Text] [Related]
58. Toll-like receptors and hepatitis C virus infection. Gao Y; Nepal N; Jin SZ Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):521-529. PubMed ID: 34419367 [TBL] [Abstract][Full Text] [Related]
59. HCV genetic variability: from quasispecies evolution to genotype classification. Argentini C; Genovese D; Dettori S; Rapicetta M Future Microbiol; 2009 Apr; 4(3):359-73. PubMed ID: 19327119 [TBL] [Abstract][Full Text] [Related]